| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8411455 | Drug Discovery Today: Therapeutic Strategies | 2012 | 6 Pages |
Abstract
The angiotensin II type 1 receptor (AT1R) is an important drug target for hypertension and chronic heart failure. This receptor is also important in the pathophysiology of acute heart failure, stimulating both adverse and beneficial hemodynamic and renal responses. This review will discuss advances in our understanding of the molecular mechanisms of AT1R function, and how these insights have enabled the discovery of β-arrestin-biased AT1R ligands, one of which is now in clinical trials for acute heart failure (AHF) treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Jonathan D. Violin, David G. Soergel, Michael W. Lark,